CAPITAL MARKETS:
Biotech Industry Shatters Fundraising Records in 2014Ongoing fight over drug pricing overshadows industry in the new year
The biotech industry shattered records for venture investment, IPOs, and M&A in 2014 as growing enthusiasm for breakthrough technologies and rising stock prices drove investment. Overall, the global life sciences industry raised a total of $104.2 billion, up from $92.9 billion in 2013. Read More
Review / Preview
- G. Steven Burrill Issues Annual Predictions for the Biotechnology Industry
Focus to shift from promise to execution in 2015 Read More
Capital Markets
- Actavis’ $66B Purchase of Allergan Continues Record Year of M&A; Transactions for Life Sciences
Increasingly Competitive Environment for Sought-After Assets Pushes Prices Higher, Says Burrill Media. Read More - AbbVie Terminates Shire Acquisition, But M&A; Activity Remains Brisk
Total life sciences transactions through first 10 months of 2014 reach $253.3 Billion, says Burrill Media Read More - U.S. Government’s Effort to Quell Tax-Driven Acquisitions Could Slow Life Sciences Dealmaking
Nearly half of dollar volume of M&A; activity in 2014 involved inversions, says Burrill Media Read More
Finance
- Life Sciences M&A; Activity Sets Annual Record with $8.3B Roche Agreement to buy Intermune, Burrill Media Reports
Press Release Read More
Privacy
- Fitness and Personal Health Apps Could Pose Privacy Nightmare
Senator Schumer says patients’ data could be sold to third parties without their knowledge. Read More
Convergence
- Intel and Fox Foundation Team to Use Smartwatches to Track Parkinson's Patients
Data from wearable devices has potential to improve monitoring and treatment. Read More
Initial Public Offerings
- Otonomy Raises $100M in Upsized IPO
Seventy-seven life sciences companies raised $5.8 billion through IPOs by mid-August. Read More
Drug Spending
- Payers Look to Curb Spending on Specialty Drugs
Podcast: August 18, 2014 Read More
Dealmaking
- Sanofi Licenses Rights to MannKind’s Afrezza for Up to $925M
After many years of struggling, biotech lands marketing partner for inhaled insulin. Read More
- The Burrill Report (August 18, 2014): Payers Look to Curb Spending on Specialty Drugs
Listen to the latest edition from The Journal of Life Sciences. Browse all podcasts
Kuldip Dave, director of research programs for the Michael J. Fox Foundation, discusses encouraging early-stage results for Affiris' experimental therapeutic vaccine for Parkinson's, what the results tell us, and why alpha-synuclein may be a compelling target in the fight against Parkinson’s disease.
Capital Scorecard
Filed IPOs
Completed IPOs
PDUFA Dates
Drug Approvals
Burrill Indices
Biggest Movers
Breakthrough Therapies
Non-traditional partnering deals have become the norm over the past few years as Big Pharma has shifted its resources away from internal R&D to outsourcing innovation. Such was the case over the past week as Bristol-Myers Squibb and Astellas Pharma partnered to access biopharmaceutical innovation coming out of academia and research institutes.
.jpg)
